Company intelligence / Profile preview

NearWave

South Bend, Indiana, United Statesnearwave.co ↗

Ownership: Private
Development stage: Commercial

Overview

Multi-center studies have shown that the technology can predict pathologic complete response to neoadjuvant chemotherapy in breast cancer patients as early as one week after treatment initiation. This enables rapid therapy adjustment compared to traditional methods that take months. The device has demonstrated promising results differentiating benign from malignant tumors non-invasively but remains investigational at this time

Therapeutic areas: OncologyCardiovascular
Modalities: DeviceNon-pharmacological therapy (fdNIRS-based imaging)
Industry: Medical Imaging

Partnerships

University of Notre Dame (technology origin & ongoing collaboration)

Beyond the preview

Go deeper on NearWave.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NearWave.

Explore the full profile